BerGenBio

Selective AXL inhibitors

Home  /  Investors

Investors

Quarterly Reports

Q1 2019 Report

Wednesday, 8 MayFelix Konferansesenter, Bryggetorget 3, 0125 Oslo

The webcast will be streamed LIVE and the recording will be available after LIVE session is finished.

Link to live webcast

Corporate Presentation

BerGenBio Corporate Update

June 2019

Read More

Share price

BerGenBio ASA

BGBIO (Norway: Oslo)

Share Price Chart

News

Latest News

BerGenBio presents preliminary Phase II clinical data at EHA 24: bemcentinib in combination with low dose chemotherapy yields durable responses in AML patients unfit for intensive chemotherapy

BerGenBio presents new Phase II clinical data that bemcentinib in combination with low dose chemotherapy improves efficacy and duration of survival in elderly AML patients at ASCO 2019

BerGenBio presents new preliminary clinical and biomarker data showing durable response & median survival rates in Phase II trial with bemcentinib and KEYTRUDA in patients with advanced NSCLC at ASCO 2019

More News

Scientific Presentations

EHA 24, Hellesøy et al

June 13 - 16 2019Amsterdam, Netherlands

Single Cell Signaling Pharmacodynamics in a Phase 1b Clinical Trial of the AXL inhibitor bemcentinib in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Read More

Annual Report 2018

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Events

Upcoming Events

BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference 2019, April 7-9

37th Annual J.P. Morgan Healthcare Conference 2019, January 7-10

DNB Healthcare Conference 2018, December 12

60th ASH Annual Meeting & Exposition 2018, December 1-4

Jefferies 2018 London Healthcare Conference, November 14-15

More Events